ISG MASTERCLASS (V) 2024: CHAPTER 4- Approach to CHOLANGIO CARCINOMA

Name: ISG MASTERCLASS (V) 2024: CHAPTER 4- Approach to CHOLANGIO CARCINOMA
Uploaded: 2024-08-11T05:05:35.000Z
Duration: 3 h 25 s
Description: ISG CHOLANGIO CARCINOMA

Introduction to the Master Class on Cholangiocarcinoma

Overview of the Series

This is the fourth class in a series initiated during COVID-19, which gained popularity and has continued due to its relevance for both residents and practicing consultants.

The classes are presented by esteemed speakers from the Indian Society of Gastroenterology, focusing on significant topics in gastroenterology.

Topic Introduction

Today's discussion centers on the multidisciplinary management of cholangiocarcinoma, specifically intrahepatic and hilar types.

Dr. Bhaskar Nandi, an eminent consultant gastroenterologist, will lead this session.

Understanding Cholangiocarcinoma

Challenges in Diagnosis and Management

Cholangiocarcinoma is recognized as a challenging tumor due to diagnostic difficulties; obtaining tissue samples is often problematic.

There are no specific tumor markers available, making diagnosis complex; CA 19-9 has proven unreliable for monitoring.

Late Presentation Issues

Patients typically present at advanced stages when curative options are limited; palliative care becomes necessary.

Even with curative resection attempts, recurrence rates remain high.

Multidisciplinary Approach

Importance of Team Management

A multimodality approach involving various specialists (hepatologists, interventional radiologists, oncologists, surgeons, and pathologists) is crucial for effective management of cholangiocarcinoma.

Classification Focus

The session will emphasize clinical applications rather than a comprehensive review of cholangiocarcinoma literature.

Classification of Cholangiocarcinoma

Types Based on Location

Intrahepatic cholangiocarcinomas arise from second-order bile ducts and typically present as mass lesions.

Perihilar cholangiocarcinomas occur at the junction where cystic duct meets second-order bile ducts; they usually manifest as malignant strictures.

Distal Cholangiocarcinomas

These tumors develop below the cystic duct insertion up to the ampulla; understanding their classification aids in management strategies.

Bismuth Classification

Stricture Types

Bismuth classification includes four types:

Type I: Stricture within 1 cm of confluence with patent confluence.

Type II: Strictures limited to confluence but blocked.

Type III: Complex strictures affecting right or left ducts.

Type IV: Bilateral multifocal strictures that pose significant treatment challenges.

Classification of Cholangiocarcinoma Growth Patterns

Overview of Tumor Classification

The classification of cholangiocarcinoma is based on growth patterns, which is crucial for understanding molecular classifications.

Three main types are identified: mass-forming, periductal infiltrating, and intraductal tumors. Each type has distinct characteristics in terms of morphology and behavior.

Mass-Forming Cholangiocarcinoma

Mass-forming cholangiocarcinomas exhibit aggressive behavior with early invasion into bile duct branches and a tendency for intrahepatic metastasis.

Surgical resection or liver transplantation decisions are complicated by the late detection of metastases, often only identified during staging or surgery.

Periductal Infiltrating Tumors

Periductal infiltrating tumors have the worst prognosis due to early lymphatic spread along the bile ducts, making them challenging to biopsy effectively.

Biopsy difficulties arise from the nature of these tumors; often treatment must proceed without a definitive tissue diagnosis.

Intraductal Growth Characteristics

Intraductal tumors typically present earlier due to duct obstruction leading to jaundice, resulting in better prognoses compared to other types.

Molecular profiling becomes essential as it aids in understanding tumor behavior and guiding targeted therapies.

Importance of Molecular Profiling

Need for Molecular Profiling

As cholangiocarcinomas often present late, molecular profiling is critical for determining appropriate targeted therapies post-surgical intervention.

Tissue samples should be sent for profiling to inform oncologists about potential therapeutic targets.

Intrahepatic Cholangiocarcinoma Variants

Intrahepatic cholangiocarcinomas can arise from small or large bile ducts, influencing their progression and treatment strategies.

Risk Factors and Pathology

Risk Factors Associated with Cholangiocarcinoma

Common risk factors include hepatolithiasis, primary sclerosing cholangitis (PSC), congenital biliary cystic disease, liver cirrhosis, and choledocholithiasis.

Challenges in Diagnosis

Diagnosing large duct variants can be complex due to variable growth patterns; however, mass-forming presentations simplify diagnosis compared to infiltrative forms.

Biliary Inflammation as a Key Factor

Underlying Causes of Cholangiocarcinoma Development

Persistent biliary inflammation and stasis are significant contributors to cholangiocarcinoma development across various risk factors.

Understanding Cholangiocarcinoma: Insights from Indian Studies

Overview of Risk Factors and Incidence

The discussion begins with the established risk factors for cholangiocarcinoma, noting that while some are well-documented, others remain probable. The speaker emphasizes a higher prevalence in Eastern Asian countries compared to Western nations.

Current State of Research in India

A review of the Indian situation reveals a lack of significant case series; most data consists of small case reports. Notably, one substantial study from Kochi documents 137 cases with a mean patient age of 62 years.

Surgical Outcomes and Mortality Rates

Curative resection rates for cholangiocarcinoma are alarmingly low, with only a few patients eligible for such procedures. The one-year mortality rate is notably high among these patients, indicating poor prognosis.

Comparative Analysis of Case Series

A larger series from T Memorial Hospital in Mumbai includes 760 patients with intrahepatic and hilar cholangiocarcinomas. This study highlights an increasing incidence of intrahepatic types globally but notes classification issues due to overlapping ICD codes between intrahepatic and perihilar cases.

Presentation Patterns and Disease Staging

Perihilar cholangiocarcinomas tend to present at earlier stages (localized) due to obstructive jaundice symptoms, whereas intrahepatic cases often present as metastatic disease at diagnosis—over two-thirds are already advanced by the time they seek treatment. This distinction is crucial for understanding treatment options and outcomes.

Diagnostic Approaches

Diagnosis involves imaging techniques (CT scans), endoscopy, tumor markers, and biopsies when malignancy is suspected. CT scans are essential for initial assessments; however, PET CT should be used selectively based on individual cases rather than routinely applied pre-operatively.

Imaging Techniques in Cholangiocarcinoma Evaluation

Contrast-enhanced MRIs or MRCPs are preferred for evaluating biliary involvement before performing ERCP or ultrasound procedures to ensure accurate mapping of biliary anatomy prior to intervention strategies. General principles emphasize the importance of both CT and MRI in assessing ductal involvement effectively.

Differentiating Intrahepatic Carcinomas

Importance of Imaging Techniques

Delayed phase imaging is crucial for differentiating intrahepatic carcinomas from hepatocellular carcinoma (HCC) during CT protocol planning.

CT scans are primarily used to identify hypodense lesions with capsular retraction, although this feature is only present in less than one-third of cases.

Enhancements and Washout Patterns

MRI plays a significant role, especially for perihilar lesions, where contrast administration enhances visualization on delayed imaging.

Understanding the enhancement patterns in HCC versus cholangiocarcinoma is essential; HCC typically shows arterial enhancement with rapid washout, while cholangiocarcinoma exhibits centripetal filling on delayed images.

Key Differentiation Points

Cholangiocarcinoma encases portal vein branches without forming thrombus, contrasting with HCC's tendency to invade as a tumor thrombus.

Irregular thickening of ducts can indicate malignancy; asymmetrical and long segment thickening are critical points for differentiation between benign and malignant structures.

Identifying Malignant vs. Benign Structures

Diagnostic Challenges

Distinguishing between benign and malignant strictures involves recognizing subtle features that may not be definitive but aid in diagnosis.

Collaboration with radiology colleagues is vital for accurate interpretation of imaging studies to differentiate between conditions like cholangiocarcinoma and HCC.

Clinical Implications of Biopsy

The risk of tumor seeding during biopsy procedures raises concerns about its clinical significance, particularly when considering curative resection or liver transplantation.

Imaging Parameters for Diagnosis

Practical Considerations in Imaging

On CT scans, mass lesions and nodal involvement (nodes larger than 1 cm) are key indicators of malignancy; atrophy or hypertrophy patterns alone do not provide clear differentiation.

MRI Insights

MRCP is valuable; multivariate analysis indicates that irregular margins, asymmetric lesions, and stricture lengths over 1 cm correlate strongly with malignancy.

Laboratory Indicators Supporting Imaging Findings

Laboratory Parameters Correlating with Malignancy

A study from PGI Chandigarh identified elevated alkaline phosphatase (>470), CA 19–9 (>100), and bilirubin levels (>8 mg/dL), which support the suspicion of malignant structures alongside imaging findings.

This structured approach provides a comprehensive overview while maintaining clarity through organized headings and bullet points linked to specific timestamps.

Understanding Maling Structure and ERCP Challenges

Overview of Maling Structure Classification

The discussion begins with the classification of maling structures based on the bisou classification, emphasizing the importance of distinguishing between benign and malignant cases.

The speaker raises concerns regarding issues in Endoscopic Retrograde Cholangiopancreatography (ERCP), particularly when suspecting higher structures without clear information about intra-ductal strictures.

Contrast Use in ERCP

A dilemma is presented regarding the use of contrast during ERCP; not using it may lead to inadequate drainage, while using it could increase the risk of colangitis.

The speaker discusses alternative methods like air contrast, which can also be effective for diagnosing ascending cholangitis without exposing patients to additional risks.

A contrasting opinion from Dr. Nageshwar R suggests that a contrast cogram provides better delineation of segment involvement compared to an air cogram.

Diagnostic Techniques Post-ERCP

After performing ERCP, brush cytology is commonly used for diagnosis; however, its sensitivity ranges only from 20% to 40%, raising questions about its reliability.

The effectiveness of increasing passes during brush cytology is debated; literature suggests that even with 30 passes, sensitivity improves only marginally.

Limitations and Alternatives in Diagnosis

There are discussions around whether dilating strictures before brush cytology improves diagnostic yield; findings indicate no significant benefit.

Introduction of biopsy forceps presents challenges; obtaining tissue samples for further studies like FISH requires advanced facilities that many centers lack.

Observations from Coloscopy Findings

Coloscopy findings reveal significant mucosal changes such as thickening and debris accumulation near strictures, indicating potential malignancy.

A systematic review highlights various studies involving coloscopy, showcasing its role in identifying pathological conditions within biliary systems.

Colonoscopy and Endoscopic Ultrasound in Cholangiocarcinoma Management

Importance of Sensitivity and Specificity in Diagnosis

Dr. Matu highlights the effectiveness of colonoscopy-guided biopsy for diagnosing cholangiocarcinoma, noting its high sensitivity and specificity.

While effective in high-volume centers, challenges arise in other settings where obtaining biopsies can be difficult due to structural access issues.

Advancements with Endoscopic Ultrasound (EUS)

EUS has significantly improved staging and reliability in cholangiocarcinoma management by enhancing tumor detection and assessing vascular involvement.

Key characteristics of malignant lymph nodes include size (preferably >1 cm), round shape, homogeneous echogenicity, and well-defined margins, contrasting with reactive lymph nodes that are often heterogeneous.

Clinical Impact of EUS on Cholangiocarcinoma

EUS outperforms CT scans in detecting vascular and nodal involvement, crucial for accurate disease management.

It accurately identifies unresectable disease in 83% of patients, allowing for timely palliative care decisions rather than unnecessary surgical interventions.

Diagnostic Accuracy and Limitations

EUS demonstrates a 97% accuracy rate for identifying resectable cases, making it a vital tool for clinical decision-making regarding cholangiocarcinoma.

Despite its strengths, negative predictive values can vary significantly across studies (as low as 29%), indicating the need for further evaluation even after a negative result.

Challenges Associated with EUS Implementation

The combination of CT imaging with EUS enhances staging capabilities but requires skilled practitioners to navigate technical difficulties effectively.

A steep learning curve exists; high-volume centers are essential to ensure accurate execution of procedures like fine needle aspiration (FNA).

Molecular Profiling Advances

Recent studies emphasize the importance of molecular testing on tissue samples from cholangiocarcinoma patients focusing on fibroblast growth factor receptors, isocitrate dehydrogenase mutations, and HER2 receptors.

This molecular profiling aids targeted therapies similar to those used in breast cancer treatment.

Understanding TNM Classification and Therapeutics in Malignancies

TNM Classification Challenges

The TNM classification for malignancies is complex; it's crucial to keep it accessible for reference.

T2 staging is significant as it indicates the need for adjuvant chemotherapy post-surgical resection, applicable to both intrahepatic and periductal tumors.

Extended hepatectomy may be performed at T2 stage, but it must be followed by chemotherapy.

Clinical Differentiation of Blockages

A question arises on how to clinically differentiate between higher versus distal blockages in biliary obstruction cases.

Distal blockages often present with a palpable gallbladder lump; however, abdominal pain and jaundice levels do not significantly differ between types of blockages.

Ultrasound is the first step in diagnosing obstructive jaundice, helping identify upstream bile duct dilation indicative of lower blockage.

Imaging Modalities for Diagnosis

High-resolution contrast CT scans are preferred when suspecting intrahepatic issues; MRI and MRCP also play vital roles in staging and assessing resectability.

All three imaging modalities (CT, MRI, MRCP) complement each other rather than substituting one another.

Multimodal Treatment Approaches

The discussion emphasizes multimodality treatment options including surgery, chemotherapy, radiation therapy, targeted immunotherapy, and local regional therapies like TACE (transarterial chemoembolization).

Local therapies such as radiofrequency ablation are increasingly utilized across various centers to improve patient survival rates.

Surgical Interventions Insights

Data from Tata Memorial Hospital shows that only about 28% of patients undergo curative surgical interventions; most receive palliative chemotherapy instead.

Despite limited surgical opportunities, identifying patients suitable for definitive surgery or transplantation remains critical for improving overall survival rates.

R0 resection (complete tumor removal with negative margins) is the surgical goal; pre-operative biopsies are not always necessary but can be essential if tumors are unresectable.

Surgical Considerations in Hepatobiliary Surgery

Contraindications for Surgery

Metastatic disease with type four higher duct involvement, bilateral vascular involvement, and multifocal obstructions are contraindications for surgery.

Lymph node spread beyond the porta hepatis is a significant concern; however, limited nodal involvement at the porta is not an absolute contraindication.

Intraoperative findings of metastatic disease or vascular involvement may necessitate abandoning curative resection.

Pre-operative Biliary Drainage

Different surgical units have varying protocols regarding pre-operative biliary drainage; some advocate for it before chemotherapy or surgery.

Surgeons often prefer to avoid stenting due to concerns about inflammation affecting tumor staging during surgery.

Pre-operative biliary drainage may be necessary based on future liver remnant calculations and overall patient health.

Assessing Surgical Eligibility

A thorough assessment of cholangiocarcinoma cases includes evaluating eligibility for curative surgery, considering comorbidities and future liver remnant (FLR).

Portal vein embolization may be performed if FLR is below 25% in normal livers or 40% in cirrhotic livers to promote hypertrophy of the non-resectable lobe.

Treatment Strategies Post-Surgery

If localized disease is identified, surgical intervention may proceed; however, locally advanced unresectable cases might require downstaging through neoadjuvant therapies.

Even after curative resections, survival rates remain low with high recurrence rates within one year post-surgery.

Recurrence Management

Upon recurrence of cholangiocarcinoma, aggressive centers consider repeat hepatectomy as a treatment option despite limited literature supporting its efficacy.

Palliative therapy options include systemic therapies and local regional treatments when repeat surgeries are not feasible.

Liver Transplantation and Cholangiocarcinoma: Insights and Protocols

Overview of Cholangiocarcinoma and Liver Transplantation

Cholangiocarcinoma is a complex condition where liver transplantation is considered viable, particularly for hiler types, but not typically for intrahepatic cases. The Mayo protocol has popularized this approach.

The Mayo Protocol Explained

The Mayo protocol involves a multi-step process including staging, external beam radiation therapy (EBRT), brachytherapy, chemotherapy, and further staging through exploratory laparotomy to determine transplant eligibility based on specific criteria.

Survival Rates and Challenges

For non-cholangiocarcinoma patients undergoing transplantation under the Mayo protocol, survival rates are comparable; however, recurrence rates can be as high as 14%. Few centers successfully implement this protocol consistently.

Comparative Outcomes in Surgical Data

Studies indicate that patients meeting Milan criteria who undergo liver transplantation show better overall survival compared to those receiving surgical resection alone. This raises questions about the viability of transplantation in certain cases.

Considerations in Indian Context

In India, live donor liver transplantation presents unique challenges. Decisions regarding surgery versus transplantation depend on factors like disease stage and underlying cirrhosis. Cost considerations also play a significant role.

Principles of Biliary Drainage

Importance of Adequate Biliary Drainage

Adequate biliary drainage is crucial; draining 33% of the liver suffices for preserved function while over 50% is necessary for impaired function. Optimal drainage volume for malignant obstruction should exceed 71%.

Techniques for Biliary Drainage

Unilateral vs bilateral drainage strategies depend on the obstruction type. Various modalities such as plastic stents or self-expanding metal stents (SEMS), ERCP, or PTBD are evaluated based on clinical scenarios.

Role of Radiological Mapping

Effective radiological mapping (e.g., MRCP) is essential before planning biliary drainage to assess cholangiocarcinoma extent accurately. This informs whether unilateral or bilateral drainage is required.

Recommendations Against Plastic Stents

There’s a strong recommendation against using plastic stents due to complications experienced in practice; instead, SEMS or PTBD are preferred methods for biliary drainage.

Initial Management Strategies

When encountering suspected malignant strictures, histopathology should ideally guide management decisions rather than relying solely on clinical evidence before placing any stent.

Colangio Carcinoma Management: Stenting Strategies

Stenting Approaches and Considerations

The discussion begins with the consideration of using a plastic stent before transitioning to a metallic stent, suggesting that this practice may reduce complications such as colitis and overall morbidity.

A plastic stent can serve as an initial evaluation tool to confirm correct drainage of the biliary system while assessing resectability, allowing for effective decompression.

Emphasizes the importance of obtaining a comprehensive imaging roadmap (e.g., contrast resolution CT or MRCP) prior to intervention to determine appropriate drainage strategies.

Highlights that literature indicates only 30-40% of patients are deemed resectable in certain regions, raising concerns about complacency in assuming unresectability without thorough evaluation.

The speaker stresses the need for careful assessment of resectability before deciding on drainage methods, advocating for collaboration with radiology for optimal planning.

Unilateral vs. Bilateral Stenting

A busy slide presents recent studies comparing unilateral and bilateral stenting; findings suggest no significant difference in successful drainage rates between the two approaches in unresectable cases.

Older studies support similar conclusions, but newer multicenter trials indicate that bilateral metal stents may offer better patency and overall survival compared to unilateral placements.

Metal stents consistently outperform plastic ones regarding clinical success rates; even unilateral metal stents show superior outcomes compared to bilateral plastic options.

Questions remain about best practices across different centers regarding initial placement strategies—whether to use metal or plastic stents first—and their implications on patient outcomes.

The consensus leans towards preferring bilateral metal stents when feasible, especially in cases assumed unresectable due to lack of thorough reevaluation.

ERCP vs. PTBD: Choosing the Right Approach

Discussion shifts towards ERCP versus PTBD; many centers prefer ERCP for type 1 obstructions but opt for PTBD in more complex types (type 3 and 4).

Systematic reviews indicate that PTBD generally yields better results than endoscopic drainage methods across various obstruction levels, particularly where strictures are more severe.

The effectiveness of PTBD is attributed to its suitability for higher-grade strictures (types 3 and 4), leading practitioners to question whether endoscopic approaches should be attempted at all in these scenarios.

There is ongoing debate about whether endoscopic techniques should still be considered if good mapping suggests potential success with major segment drainage through ERCP.

This structured summary captures key discussions from the transcript while providing timestamps for easy reference.

Clinical Experience with PTBD vs. Endoscopic Drainage

Patient Preferences and Clinical Outcomes

The overall clinical experience with percutaneous transhepatic biliary drainage (PTBD) is reported to be better than endoscopic approaches, particularly in type IV cases, but patient comfort plays a significant role in the choice of procedure.

Patient acceptability favors endoscopic drainage over PTBD due to comfort concerns, especially when discussing both modalities with patients.

Dr. Gar prefers PTBD for types III and IV directly rather than opting for endoscopy; however, the appropriateness of each method can depend on specific scoring systems used in practice.

Technical Considerations and Efficacy

For higher blockages, PTBD is often deemed more appropriate compared to endoscopic methods; type I and II are generally easier to manage through PTBD techniques.

The introduction of ultrasound-guided biliary drainage has added complexity; it allows for various approaches such as draining left or right systems effectively.

Challenges and Success Rates of Biliary Drainage Techniques

Technical Expertise Requirements

The success of ultrasound-guided drainage heavily relies on the technical expertise available at the center performing the procedure.

Studies indicate high clinical success rates (over 90%) across different drainage methods, emphasizing that skilled practitioners are crucial for achieving these outcomes.

Comparative Effectiveness

A study comparing ERCP combined with other techniques against PTBD showed that while technical success was high for both methods, patient acceptability remains a concern primarily associated with PTBD procedures.

Future Directions in Biliary Drainage Techniques

Viable Options and Quality of Life Concerns

While ultrasound-guided biliary drainage presents a viable option with promising results, quality-of-life issues related to patient preferences must be considered when choosing between techniques.

There is currently no direct comparative trial between ultrasound-guided drainage and PTBD specifically for higher obstructions; this area requires further research.

Guidelines and Recommendations

ASG guidelines suggest that decisions regarding palliative drainage should depend on local expertise rather than favoring one technique universally.

Treatment strategies for unresectable pancreatic carcinoma include chemotherapy, targeted therapies, and immunotherapies; understanding these options typically benefits from discussions within tumor board meetings.

Chemotherapy and Targeted Therapies in Cancer Treatment

Overview of Current Treatments

Chemotherapy has traditionally been the standard treatment, but targeted therapies like Capsian are now becoming mainstream.

Immune checkpoint inhibitors, such as PD-1 and CTLA-4 inhibitors, have shown promise in treating various cancers, including hepatocellular carcinoma (HCC).

CAR T-cell therapy is emerging for cholangiocarcinoma, previously approved mainly for leukemia patients.

Efficacy and Quality of Life Considerations

Studies indicate that targeted and immunotherapies may provide only 6 to 12 months of additional survival time.

The quality of life during treatment is a significant concern; discussions with patients about expectations are crucial.

Patients often face difficult choices regarding spending their remaining time in hospitals versus enjoying life at home.

Molecular Profiling and Treatment Strategies

A molecular profile lab is being developed to identify key receptors for targeted therapy in cholangiocarcinoma.

Patient classification into localized, locally advanced, or metastatic disease stages is essential for determining treatment plans.

Surgical Options and Challenges

For localized disease without vascular involvement, surgical resection is preferred; post-surgery chemotherapy may be necessary if margins are not clear.

The debate continues on whether liver transplantation offers better outcomes than R0 resection due to organ availability issues.

Advanced Disease Management

Locally advanced unresectable cases require strategies like downstaging through neoadjuvant chemotherapy or radiotherapy before considering surgery.

If the disease remains unresectable after downstaging, options include chemotherapy, targeted therapy, immunotherapy, and radiation treatments.

Multidisciplinary Approach to Treatment

Effective management of cholangiocarcinoma necessitates a multimodal approach involving various specialists to improve patient outcomes.

Continuous follow-up from high-volume centers is vital for developing clear algorithms for treatment protocols.

Therapeutic Options and Management in Hepatobiliary Diseases

Overview of Treatment Strategies

The discussion highlights the importance of identifying the best therapeutic options for hepatobiliary diseases, emphasizing that curative resection is feasible for a limited number of patients.

Liver transplantation is noted as a viable option in selected cases, indicating the need for careful patient selection based on specific criteria.

The role of biliary drainage is underscored as crucial in managing these conditions, alongside emerging successes in targeted immunotherapy.

Key Takeaways from the Presentation

Dr. emphasized the comprehensive coverage of both intrahepatic and extrahepatic pathologies during his talk, which received positive feedback for its thoroughness.

Early diagnosis is critical; extensive investigation into disease reliability should be prioritized to improve outcomes.

There may be a tendency to rush into biliary drainage procedures; thus, careful patient selection is essential to identify those who can benefit from surgical intervention.

Collaborative Approach to Patient Management

A multidisciplinary team approach involving radiologists, oncologists, surgeons, and gastroenterologists is vital for effective disease management.

The decision-making process regarding biliary drainage should consider various factors including patient preferences and local expertise rather than applying a one-size-fits-all strategy.

Not all patients require biliary drainage; it should be reserved for those with significant cholangitis or ascites or those who are candidates for chemotherapy or radiotherapy aimed at improving quality of life.